Free tool
FAERS Monitor: Regranex
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 103691 or its brand name (Regranex, Becaplermin). Reports on generic versions are filed under their own applications.
Reports
1
Serious
1
100% of reports
Hospitalization
1
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- abdominal pain lower1
- ammonia increased1
- ascites1
- blood glucose increased1
- hepatic cirrhosis1
- hepatic encephalopathy1
- increased tendency to bruise1
- international normalised ratio increased1
- iron deficiency anaemia1
- lymphoma1
- pancytopenia1
- pleural effusion1
- splenomegaly1
- thrombocytopenia1
- white blood cell count decreased1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,158 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| ammonia increased | 1 | 4123.4 | 4011.9 | 1,030 |
| increased tendency to bruise | 1 | 2286.3 | 2240.0 | 571 |
| iron deficiency anaemia | 1 | 2278.8 | 2232.8 | 569 |
| hepatic encephalopathy | 1 | 2254.4 | 2209.2 | 563 |
| splenomegaly | 1 | 1794.6 | 1762.4 | 448 |
| lymphoma | 1 | 1361.7 | 1340.4 | 340 |
| hepatic cirrhosis | 1 | 1119.9 | 1104.0 | 279 |
| abdominal pain lower | 1 | 832.0 | 821.9 | 207 |
| international normalised ratio increased | 1 | 737.7 | 729.2 | 184 |
| ascites | 1 | 715.5 | 707.3 | 178 |
| pancytopenia | 1 | 376.4 | 373.3 | 93 |
| pleural effusion | 1 | 345.6 | 342.9 | 86 |
| white blood cell count decreased | 1 | 194.0 | 192.9 | 48 |
| thrombocytopenia | 1 | 188.1 | 187.0 | 46 |
| blood glucose increased | 1 | 111.6 | 111.1 | 27 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.